When it comes to deadly viruses, what's in a name?
For a pathogen with such a short history, the mysterious new virus killing people in the Middle East and Europe has already had an amazing array of names. Full Article
REUTERS SHOWCASE
Reuters India Mobile
Get the latest news on the go. Visit Reuters India on your mobile device. Full Coverage
Gilead signs deals with Indian companies for low-cost HIV drug
 |
The many faces of Sreesanth
The various emotions and reactions of Shanthakumaran Sreesanth on and off the cricket field. Slideshow
(Reuters) - Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries.
Under deals with Ranbaxy Laboratories, Strides Arcolab and Mylan Inc's India unit, Gilead will provide technology and funding to help reduce manufacturing costs of the drug, the companies said.
Gilead, which sells the drug under the Emtriva brand, is the world's largest maker of branded drugs to treat the human immunodeficiency virus -- the cause of AIDS.
(Reporting by Shailesh Kuber; Editing by Viraj Nair)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters